Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1994-07-12
1997-04-01
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514108, 514292, A61K 31675, A61K 3144
Patent
active
056165765
ABSTRACT:
PQQ and PQQ-generating compounds inhibit osteoclast cell formation and bone resorption, and those compounds can be used to treat medical conditions characterized by undesired bone resorption. PQQ-phosphonates that target osteoclasts at the bone-mineral interface are particularly useful in this regard.
REFERENCES:
patent: 4898870 (1990-02-01), Narutomi
patent: 5061711 (1991-10-01), Urakami
Beard et al., J. Lab. Clin. Med. 108:498-505 (1986).
Beug et al., Cell 18:375-390 (1979).
Cole and Walters, J. Histochem. Cytochem. 35:203-206 (1987).
Gallop et al., Connective Tissue Research 27:74 (1992).
Garrett et al., J. Clin. Invest. 85:632-639 (1990).
Key et al., Bone 11:115-119 (1990).
Krukowski and Kahn, Calci, Tissue Int. 34:474-479 (1982).
Takahashi et al., Endocrinology 122:1373-1382 (1988).
MacIntyre et al., Proc. Natl. Acad. Sci. USA 88:2936-2940 (1991).
Ries et al., J. Bone Miner. Res. 7:931-939 (1992).
Gallop Paul M.
Hauschka Peter V.
Criares Theodore J.
The Children's Medical Center Corporation
LandOfFree
Controlling bone resorption with pyrroloquinoline quinone (PQQ) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlling bone resorption with pyrroloquinoline quinone (PQQ) , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlling bone resorption with pyrroloquinoline quinone (PQQ) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-539002